Novel Lipid Biomarkers and Microvascular Complications in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis

Abstract

Background:

Emerging lipid-related biomarkers, including the Visceral Adiposity Index (VAI), Lipid Accumulation Product (LAP), and Atherogenic Index of Plasma (AIP), have demonstrated potential in predicting metabolic disorders such as diabetes mellitus (DM) and associated microvascular complications, particularly diabetic kidney disease (DKD) and diabetic retinopathy (DR).

Objectives:

This systematic review and meta-analysis aims to evaluate the association between these biomarkers and microvascular complications in individuals with DM, as well as to assess their diagnostic performance.

Data sources and methods:

A systematic literature search was performed in PubMed, Scopus, Embase, and Web of Science following PRISMA guidelines. Eligible studies examined the relationship between VAI, LAP, and AIP and microvascular complications in DM. The meta-analysis synthesized data using pooled weighted mean differences (WMDs) and area under the receiver operating characteristic curve (AUC) values to evaluate the predictive utility of these biomarkers for DKD and DR.

Results:

A total of 23 studies were included. Patients with DKD had significantly higher levels of LAP (WMD: 12.67; 95% CI: 7.83–17.51; P < .01), AIP (WMD: 0.11; 95% CI: 0.03–0.19; P < .01), and VAI (WMD: 0.63; 95% CI: 0.38–0.89; P < .01) compared to those without DKD. Additionally, each 1-unit increase in LAP (OR: 1.005; 95% CI: 1.003–1.006; P < .01), AIP (OR: 1.08; 95% CI: 1.04–1.12; P < .01), and VAI (OR: 1.05; 95% CI: 1.03–1.07; P < .01) was associated with an elevated risk of DKD. In contrast, no significant associations were identified between these biomarkers and DR. The diagnostic performance of VAI, LAP, and AIP was limited for both DR and DKD, with low discriminatory power.

Conclusion:

VAI, LAP, and AIP are significant predictors of DKD in individuals with DM but exhibit limited relevance for the detection of DR. Although these biomarkers show potential in identifying DKD risk, their overall diagnostic accuracy for DKD and DR remains modest, underscoring the need for further studies to enhance their clinical applicability.

Plain Language Summary

Can Lipid Biomarkers Help Predict Complications in diabetes mellitus?

Why This Study Was Done: Diabetes diabetes can lead to serious complications like kidney disease and vision problems. Researchers are looking for new ways to predict these complications early on. Emerging lipid biomarkers, such as VAI, LAP and AIP show promise in predicting metabolic issues. What the Researchers Did: The team conducted a comprehensive review and analysis of studies that looked at how these lipid biomarkers are linked to kidney disease and vision problems in people with diabetes mellitus. What They Found: The analysis included data from 23 studies. It showed that patients with kidney disease had higher levels of these biomarkers compared to those without. However, these biomarkers were not as effective in predicting vision problems. What It Means: This study suggests that certain lipid biomarkers can help identify people with diabetes mellitus who are at risk of developing kidney disease. However, more research is needed to see if these biomarkers are better than traditional methods for managing diabetes and predicting other complications.

Keywords

diabetes mellitus visceral adiposity index lipid accumulation product atherogenic index of plasma microvascular complications

Introduction

Diabetes mellitus (DM) is a complex disorder characterized by insulin resistance (IR), often accompanied by varying degrees of defects in insulin secretion. This condition ultimately leads to impaired insulin release from pancreatic beta cells.¹ The increasing incidence of diabetes has coincided with a rise in related complications that significantly affect morbidity and mortality, particularly in countries with low and middle socioeconomic status.^2,3 Chronic hyperglycemia is known to inflict damage on small blood vessels, thereby increasing the likelihood of microvascular complications in patients with DM, especially those with longer disease duration.⁴ These complications, such as diabetic retinopathy (DR), diabetic kidney disease (DKD), and diabetic neuropathy (DN), substantially threaten patient health and compromise quality of life (QoL).⁵ Microvascular complications predominantly arise in tissues where glucose uptake does not rely on insulin, such as the kidneys, retina, and vascular endothelium. These tissues are particularly vulnerable as they experience glucose concentrations closely aligned with blood glucose levels.⁶ Addressing these comorbidities necessitates a comprehensive and interdisciplinary approach to diabetes management, emphasizing the need for coordinated care strategies to improve patient outcomes.⁷

Adipose tissue plays a significant role in the pathophysiology of DM and its associated complications. Adipose tissue can be found as subcutaneous adipose tissue (SCAT) and visceral adipose tissue (VAT) throughout the body. SCAT differs from VAT in several aspects, including anatomical, cellular, and molecular characteristics.⁸ VAT contains more inflammatory and immune cells, a lower preadipocyte differentiating capacity, and a greater proportion of large adipocytes. These adipocytes exhibit increased sensitivity to lipolysis and greater insulin resistance than those in SCAT.^8,9 VAT adipocytes are also more metabolically active and secrete a range of bioactive substances that influence systemic metabolism, making VAT a stronger predictor of adverse outcomes.^8,10

As part of the endocrine system, adipose tissue regulates several biological processes involved in energy homeostasis and metabolic function in target organs such as the liver, muscle, and pancreas.¹¹ Excess fat accumulation in non-adipose tissues has been linked to the induction of insulin resistance and impaired beta-cell function.¹¹ Recent investigations have emphasized the pivotal role of VAT in the onset of complications associated with diabetes.¹² Novel lipid parameters, including the visceral adiposity index (VAI), lipid accumulation product (LAP), and atherogenic index of plasma (AIP), have been proposed as better predictors of adverse outcomes, including metabolic syndrome,¹³ obstructive sleep apnea,¹⁴ and cardiovascular diseases.¹⁵ The VAI combines body mass index (BMI), waist circumference (WC), and lipid profiles to assess visceral fat distribution, which poses greater metabolic risks due to fat accumulation around internal organs.¹⁶ This index effectively reflects insulin resistance, inflammation, dyslipidemia, and diminished beta-cell function, providing valuable insights for patient management.^11,17 Similarly, the LAP integrates WC and triglyceride (TG) levels and has been identified as an early indicator of metabolic impairments and disruptions in lipid metabolism.¹⁸ This parameter has been associated with increased metabolic risk factors and is a biomarker for visceral adiposity.¹⁷ The AIP, calculated as the logarithmic ratio of TG to high-density lipoprotein cholesterol (HDL-C), illustrates the balance between protective and harmful lipoproteins and strongly predicts atherosclerosis and coronary heart disease.¹⁹

Therefore, the primary aim of this systematic review and meta-analysis is to assess the associations between these specific lipid biomarkers and the risk of key diabetic microvascular complications, including DKD, DR, and DN. Additionally, the study evaluates the diagnostic performance of these markers in identifying such complications. By systematically synthesizing current evidence, this study seeks to determine the clinical relevance of these biomarkers for early identification and risk assessment of microvascular complications in individuals with DM.

Methods and Materials

Protocol Registration

This study was carried out according to the PRISMA guidelines (PROSPERO registration: CRD42024596607).²⁰

Search Strategy

A comprehensive search of the electronic databases PubMed, Scopus, Embase and Web of Science was performed from the beginning to 25st April 2025. Keywords and MeSH terms related to “diabetic kidney disease,” “diabetic retinopathy,” “diabetic neuropathy,” “visceral adiposity index,” “lipid accumulation product,” and “atherogenic index of plasma” were combined using OR and AND operators, restricted to the “title/abstract” field. No limitations were placed on publication date. Study language was limited to English studies. The complete search strategy is provided in Supplemental Table 1. Two independent investigators (D.Z. and P.S.) screened studies by title and abstract in the initial stage, followed by a full-text review. Disagreements were resolved by a third reviewer (S.S.). All the screening process was conducted in EndNote version 21. The reference lists of the included studies were also reviewed to ensure that all relevant studies were incorporated.

Eligibility Criteria

Studies were included if they met the following criteria: (1) Population: Patients with diabetes mellitus (DM); (2) Intervention (Exposure): Evaluation of microvascular complications in relation to lipid profiles measured by lipid biomarkers, including the LAP, AIP and VAI; (3) Comparison/Control: Patients without microvascular complications or patients with lower ranges of biomarkers as comparison group; (4) Outcome: Comparing the lipid biomarker levels in patients with and without microvascular complications or reporting the risk of microvascular complications associated with these biomarkers.

Studies were excluded if they met any of the following criteria: (1) Absence of lipid biomarker measurements in the comparison/control group; (2) Studies including patients without DM; (3) Case reports, case series, conference abstracts, studies without full-text availability, and studies lacking control groups.

Definitions of Exposures

Included studies used the following formula to calculate lipid biomarkers:

LAP:

For men: [WC (cm)−65]×TG (mmol/L)

For women: [WC (cm)−58]×TG (mmol/L)

WC is the waist circumference, and TG is the triglyceride levels.

VAI:

For men: (WC/39.68 + BMI/1.88) × (TG/1.03) × (1.31/HDL-C)

For women: (WC/36.58 + BMI/1.89) × (TG/0.81) × (1.52/HDL-C)

WC is waist circumference, BMI is body mass index, TG is triglycerides, and HDL-C is high-density lipoprotein cholesterol.

AIP:

AIP = log10(TG/HDL-C)

Outcomes of Interest

The primary outcome of this study was to assess the association between specific lipid biomarkers (VAI, LAP, and AIP) and microvascular complications in patients with DM, specifically:

Diabetic Kidney Disease (DKD)

Diabetic Retinopathy (DR)

Diabetic Neuropathy (DN)

This outcome was measured through pooled comparisons of biomarker levels between patients with and without each complication, along with odds ratios (ORs), hazard ratios (HRs), and weighted mean difference (WMD).

The secondary outcome was the diagnostic performance of each lipid biomarker (VAI, LAP, and AIP) in detecting these complications. This was evaluated using metrics such as:

Area Under the Receiver Operating Characteristic Curve (AUC)

Sensitivity

Specificity

Cut-off values

Data Extraction

A structured data extraction sheet was developed in Excel, allowing 2 investigators, S.S. and A.M., to extract data for each study independently. The data included various study characteristics such as the first author, year of publication, study design, sample size, and country. Additionally, participant characteristics were recorded, including age, gender, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), presence of hypertension, and current smoking history. Data related to DM encompassed the type and duration of DM. The extraction also covered lipid biomarker values like VAI, LAP, and AIP, as well as the presence and type of microvascular complications. Lastly, the diagnostic power of each marker was assessed, including metrics such as the area under the receiver operating characteristic curves (AUCs), sensitivity, specificity, and cut-offs.

Quality Assessment

The quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS), a tool designed to evaluate observational studies.²¹ Each study was eligible for a maximum score of 9 points: 4 points for participant selection, 2 points for comparability, and 3 points for the assessment of outcomes and exposures. NOS scoring was independently conducted by P.S., and any discrepancies or uncertainties were resolved through consultation with H.R. to maintain consistency and objectivity in the evaluation process. Studies receiving 7 to 9 points were classified as high quality (low risk of bias), those with 4 to 6 points as moderate quality (moderate risk of bias), and those with 0 to 3 points as low quality (high risk of bias).²²

Statistical Analysis

Lipid marker values were reported as means (standard deviation, SD) or medians (interquartile range, IQR). For studies reporting continuous outcomes as medians and IQRs, the methods described by Luo et al²³ and Wan et al²⁴ were applied to convert these values to means and SDs, assuming an approximately normal distribution. This conversion facilitated consistent analysis across studies with varying summary statistics. Weighted mean differences (WMDs) were employed to compare the mean lipid marker values between patients with and without diabetic microvascular complications using restricted maximum likelihood (REML) estimation. AUC values from individual studies were pooled to obtain a single overall estimate of diagnostic performance, applying the restricted maximum likelihood (REML).²⁵ For diagnostic accuracy, AUC values were interpreted as follows: 0.50–0.59: poor, 0.60–0.69: fair, 0.70–0.79: good, and ⩾0.80: excellent discriminative ability, based on established guidelines.²⁶ Hazard ratios (HRs) from Cox regression models and odds ratios (ORs) from logistic regression models with corresponding 95% confidence intervals (CIs) were pooled separately to determine a combined effect size for the relationship between lipid biomarkers and microvascular complications. The degree of heterogeneity among the studies was assessed using Cochran’s Q test and the I² statistic, with an I² value greater than 50% and a P-value <.05 indicating substantial heterogeneity. A random-effects model was utilized to account for both within-study and between-study variability for analyses with more than 3 studies. We used fixed-effect model for analyses with only 2 studies. Meta-regression and sensitivity analyses were conducted to identify sources of heterogeneity, with each study excluded in turn to evaluate its impact on the overall estimate. Publication bias was assessed using Egger’s test.²⁷ Statistical analyses were performed using STATA version 17.0 (STATA Corp). A P-value <.05 was considered statistically significant.

Certainty of Evidence

The certainty of evidence for the analyses was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. This method assesses the strength of the body of evidence across 5 domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias. For each outcome, the quality of evidence was categorized as high, moderate, low, or very low. A Summary of Findings (SoF) table was constructed to present the pooled estimates, number of participants, number of studies, and the GRADE certainty rating for each analysis.

The overall certainty of evidence, as assessed by GRADE, was rated as very low across all outcomes (Supplemental Table 3, Summary of Findings; Supplemental Table 4, GRADE Evidence Profile). This was primarily due to concerns regarding risk of bias and inconsistency (high heterogeneity across studies). Although the Newcastle-Ottawa Scale (NOS) classified 21 of the 23 included studies as low risk of bias, the GRADE assessment considers additional dimensions beyond NOS, including inconsistency of results (I² values >90% in most comparisons), publication bias (noted for several outcomes), and the predominance of cross-sectional study designs, which may introduce residual confounding. Therefore, despite individual study quality ratings, the body of evidence was downgraded in GRADE for serious risk of bias and inconsistency.

Results

Search Process

The search resulted in 1351 studies across all databases. After excluding 156 duplicates (using EndNote), 1195 records were screened based on titles and abstracts. We removed 1163 studies from consideration as irrelevant to the review topic. A total of 32 full-text studies were retrieved and evaluated according to the inclusion and exclusion criteria. Following a full-text review, 23 studies fulfilled the criteria to be included. The search and screening process is summarized in Figure 1.

Figure 1.

Overview of the search and screening process.

Study Characteristics

A total of 23 studies were included. These studies originated from the Middle East (n = 3),^28
-30 India (n = 1),³¹ and China (n = 19)^32
-50 and were published between 2016 and 2025. The included studies used cross-sectional (n = 17), cohort (n = 5), and case-control (n = 1) designs. The duration of follow-up in the prospective cohorts varied, with an average range from 2 to 4.82 years.^32,44,47,51 In total, 52,214 patients were included, with 27,501 male participants accounting for 52.6% of the participants. The mean age of the included population ranged from 43 to 67 years (Table 1).

Table 1.

Baseline Characteristics of Included Studies.

First author	Country	Design	Sample size	Males	Mean age (years)	Lipid biomarker 1	Lipid biomarker values 1*	P-values 1	Lipid biomarker 2	Lipid biomarker values 2*	P-values 2
Chun Zhou 2022**	China	Cross-sectional	10 132	3909	62.8 ± 6.6	VAI	NA	NA	NA	NA	NA
Chunyao Li 2024	China	Cross-sectional	2508	1335	58.76 ± 0.36	VAI	DKD vs no-DKD: 3.36 ± 0.18 vs 2.76 ± 0.11	<.001	NA	NA	NA
Durak 2024	Turkey	Cross-sectional	702	406	58.9 (25–87)	VAI	MI vs NO: 6.30 [0.11–49.7] VS 5.03 [0.51–50.1]	.001	NA	NA	NA
Han Yan 2024	China	Cohort	4351	2841	53.8 ± 14.1	AIP	DKD vs no-DKD: 0.19 (−0.03, 0.45) vs 0.09 (−0.11, 0.31)	<.001	NA	NA	NA
Heng Wan 2020	China	Cross-sectional	4658	2144	67.4 ± 8.64	VAI	DKD vs no-DKD: 2.01 (1.38, 3.32) vs 1.78 (1.14, 2.79), 3.01 (1.94, 4.79) vs 2.40 (1.58, 3.61)	<.001	LAP	DKD vs no-DKD: 45.2 (31.5, 72.0) vs 38.1 (23.5, 59.3), 60.1 (38.5, 95.3) vs 44.3 (28.4, 66.1)	<.001
Heng Wan 2020	China	Cross-sectional	4658	2144	67.4 ± 8.64	VAI	DR vs no-DR: 1.83 (1.18, 2.72) vs 2.36 (1.60, 3.67), 3.01 (1.94, 4.79) vs 2.60 (1.69, 4.04)	.287, .053	LAP	DR vs no-DR: 39.1 (23.8, 59.7) vs 40.7 (25.0, 63.4), 48.1 (30.7, 74.1) vs 48.8 (30.7, 75.4)	.246, .853
Huifang Li 2024	China	Cross-sectional	1057	593	63.42 ± 10.65	AIP	DKD vs no-DKD: 0.17 ± 0.31 vs −0.08 ± 0.293	<.001	NA	NA	NA
Jia Wen 2019**	China	Cross-sectional	341	265	50.9 ± 8.8	VAI	NA	NA	NA	NA	NA
Jia Zhang 2024	China	Cohort	2943	1775	55.18 ± 11.69	AIP	DKD vs no-DKD: 0.07 (−0.13, 0.27) vs 0.12 (−0.07, 0.30)	.001	AIP	DR vs no-DR: 0.10 (−0.10, 0.29) vs 0.10 (−0.09, 0.30)	.629
Jiaheng Chen 2024	China	Cohort	1403	587	64.5 ± 7.6	LAP	DR vs no-DR: 51.70 (31.80–80.08) vs 46.55 (27.64–75.44)	.03	VAI	DR vs no-DR: 2.94 (1.79–4.54) vs 2.51 (1.47–4.37)	.003
Jingyang Wu 2019	China	Cross-sectional	427	159	61.69 ± 9.9	LAP	DR vs no-DR: 40.76 ± 39.60 vs 55.60 ± 44.51	.006	NA	NA	NA
Jinling Xu 2022	China	Cross-sectional	1098	646	NA	AIP	DR vs no-DR:0.21 ± 0.20, vs 0.18 ± 0.21	<.001	AIP	DKD vs no-DKD: 0.23 ± 0.21 vs 0.18 ± 0.21	.001
Licui Qi 2022	China	Cross-sectional	335	NA	MI: 43.13 ± 11.34, NO: 44.13 ± 12.39	AIP	MI vs NO: 0.49 (0.30, 0.69) VS 0.21 (0.03, 0.37)	<.001	NA	NA	NA
Min Tang 2023	China	Cross-sectional	931	579	55 (42-65)	LAP	DKD vs no-DKD: 60.52 (39.90–90.65) vs 45.92 (29.25–72.94)	<.001	NA	NA	NA
Miric 2016	Turkey	Cross-sectional	110	46	NA	AIP	DPN vs no-DPN: 0.366 ± 0.238 vs 0.270 ± 0.229	<.05	NA	NA	NA
Nabipoorsharafi 2023	Iran	Cross-sectional	2934	1343	Albuminuria: 56.50 ± 9.68, no albuminuria: 56.28 ± 10.83	VAI	Albuminuria vs no albuminuria: 8.50 ± 7.50 VS 7.13 ± 5.10	<.001	LAP	Albuminuria vs no albuminuria: 94.54 ± 72.90 VS 76.05 ± 49.13	<.001
Pingping Zhao 2024	China	Cross-sectional	11 776	746	NO: 59.09 ± 11.02, MI: 59.51 ± 11.23, MA: 61.54 ± 10.14	VAI	MI vs NO: 2.47 (1.62, 3.51) VS 2.22 (1.56, 2.98)	<.001	LAP	MI vs NO: 39.89 (23.97, 56.19) VS 32.62 (19.12, 47.02)	<.001
Pingping Zhao 2024	China	Cross-sectional	1176	746	NO: 59.09 ± 11.02, MI: 59.51 ± 11.23, MA: 61.54 ± 10.14	VAI	MA vs NO: 3.27 (2.11, 4.98) VS 2.22 (1.56, 2.98)	<.001	LAP	MA vs NO: 48.50 (25.29, 86.42) VS 32.62 (19.12, 47.02)	<.001
Rammaiah 2020	India	Cross-sectional	150	NA	NA	AIP	DKD vs no-DKD: 6.47 ± 1.98 vs 6.21 ± 1.65	NA	NA	NA	NA
Xiaosi Chen 2022	China	Case-control	122	73	NA	AIP	DR vs no-DR: −0.01 (−0.22 to 0.39) vs −0.02 (−0.27 to 0.07)	.180	AIP	DKD vs no-DKD: 0.03 (−0.20 to 0.23) vs −0.01 (−0.22 to 0.39)	.180
Xin Li 2021	China	Cross-sectional	263	139	NA	LAP	DR vs no-DR: 74.06 (56.41, 122.56) vs 38.16 (28.14, 62.47)	<.05	NA	NA	NA
Yue-Yang Zhang 2025**	China	Cross-sectional	3094	1645	56.09 ± 10.64	AIP	NA	NA	NA	NA	NA
Yu-Lun ou 2021	China	Cross-sectional	1872	809	64 ± 11.3	VAI	Albuminuria vs no albuminuria: 3.1 ± 3.4 vs 2.3 ± 2.4	<.001	LAP	Albuminuria vs no albuminuria: 62.6 ± 56.7 VS 44.1 ± 32.3	<.001
Zhenzhen Sun 2023	Taiwan	Cohort	2659	1307	DKD: 60.44 ± 11.62, non-DKD: 55.90 ± 10.90	LAP	DKD vs no-DKD: 31.60(19.52,50.75) vs 28.14(16.48,46.99)	<.001	VAI	DKD vs no-DKD: 1.52 (0.96, 2.48) vs 1.40 (0.88, 2.21)	<.001
Zhiyuan Wu 2022	China	Cohort	8948	6154	53.35 ± 14.66	VAI	DR vs no-DR: 1.45 (0.95, 2.32) vs 1.46 (0.89, 2.37)	.984	VAI	DKD vs no-DKD: 1.76 (1.03, 2.80) vs 1.45 (0.90, 2.36)	.043

Abbreviations: AIP, atherogenic index of plasma; DKD, diabetic kidney disease; DPN, diabetic peripheral neuropathy; DR, diabetic retinopathy; LAP, lipid accumulation product; MA, macroalbuminuria; MI, microalbuminuria; NO, no albuminuria; VAI, visceral adiposity index.

Lipid biomarker values were expressed as mean ± standard deviation or median (interquartile range).

Three studies did not report values of lipid biomarkers in patients with microvascular complications compared to controls. These studies were used in the analysis of OR and HR.

Diabetic Kidney Disease (DKD) and Lipid Biomarkers

Meta-Analysis of Lipid Biomarkers in Participants with and Without DKD or Albuminuria

Sixteen studies reported lipid biomarker values in individuals with DKD and albuminuria, compared to control groups.^{28,30,31,33
-35,37,38,40,41,44
-47,49,51} The analysis revealed significantly higher values of LAP (WMD: 12.67, 95% CI: 7.83–17.51, P < .01, Figure 2A), AIP (WMD: 0.11, 95% CI: 0.03–0.19, P < .01, Figure 2B), and VAI (WMD: 0.63, 95% CI: 0.38–0.89, P < .01, Figure 3) in patients DKD compared to those without DKD. Due to high heterogeneity, sensitivity analyses and meta-regression were performed. The omission of each study did not significantly alter the overall effect size for LAP (Supplemental Figure 1), AIP (Supplemental Figure 2), and VAI (Supplemental Figure 3) values in individuals with DKD, in contrast with those without it. Egger’s test indicated no publication bias among studies assessing LAP (P = .196) and AIP (P = .922). However, studies assessing VAI showed a significant publication bias (P = .003). Meta-regression identified mean diastolic blood pressure and HbA1c as sources of heterogeneity among studies comparing AIP in patients with and without DKD or albuminuria (Table 2).

Figure 2.

(A) Forest plot for analysis comparing the LAP levels in patients with DKD and albuminuria compared to those without these complications and (B) forest plot for analysis comparing the AIP levels in patients with DKD and albuminuria compared to those without these complications.

Figure 3.

Forest plot for analysis comparing the VAI levels in patients with DKD and albuminuria compared to those without these complications.

Table 2.

Findings from the meta-regression on the analyses comparing lipid biomarker values.

Complication	Heterogeneous factor	Biomarker	Control group	Coefficient (95% CI)	P-value	I ²
DKD	Case mean DBP	AIP	No DKD	0.012(0.0003-0.0249)	.044	66.44
	Control mean DBP	AIP	No DKD	0.017(0.001-0.024)	<.001	0
	Case mean HbA1c	AIP	No DKD	0.063(0.001-0.125)	.044	59.08
	Control mean HbA1c	AIP	No DKD	0.074(0.042-0.108)	<.001	1.94
DR	Case mean DBP	LAP	no DR	1.689122	.001	0
	Control mean DBP	LAP	no DR	1.35219	.002	0
	Case mean TG	LAP	no DR	0.324415	.006	94.46
	Control mean TG	LAP	no DR	−0.1461	.006	94.26
	Case mean SBP	VAI	no DR	0.002048	.001	0
	Control mean SBP	VAI	no DR	−0.00187	.001	0.01

Abbreviations: AIP, atherogenic index of plasma; BMI, body mass index; DBP, diastolic blood pressure; DKD, diabetic kidney disease; DR, diabetic retinopathy; HbA1c, glycosylated hemoglobin; LAP, lipid accumulation product; SBP, systolic blood pressure; TG, triglyceride; VAI, visceral adiposity index.

Additionally, some studies provided the risk values and 95% CIs.^{30,34,37,38,40,42,44
-48,50,51} The analysis indicated increased risk of DKD and albuminuria per one-unit increase of LAP (OR: 1.005, 95% CI: 1.003–1.006, P < .01, Figure 4A), AIP (OR: 1.08, 95% CI: 1.04–1.12, P < .01, Figure 4B) and VAI (OR: 1.05, 95% CI: 1.03–1.07, P < .01, Figure 4C). Sensitivity analysis showed robust results for LAP, AIP, and VAI (Supplemental Figures 4–6, respectively). Egger’s test also showed no publication bias among studies assessing LAP (P = .110), AIP (P = .088), and VAI (P = .076) in patients with or without DKD and albuminuria. Moreover, patients with the highest level of VAI showed significantly higher risk of incidence of DKD and albuminuria compared to the reference group (HR: 1.27, 95% CI: 1.17–1.39, P < .01, Figure 4D). This analysis also showed robust sensitivity analysis (Supplemental Figure 7) and no publication bias (P = .695).

Figure 4.

(A) Forest plot for assessing the risk of DKD and albuminuria per 1 unit increase of LAP, (B) Forest plot for assessing the risk of DKD and albuminuria per 1 unit increase of AIP, (C) Forest plot for assessing the risk of DKD and albuminuria per 1 unit increase of VAI, and (D) Forest plot for assessing the risk of DKD and albuminuria in patients with highest group of VAI compared to the reference group as the lowest group.

Diagnostic Efficacy of Lipid Biomarkers for DKD and Albuminuria

Six studies reported the AUC values and corresponding 95% CIs to assess the diagnostic power of lipid biomarkers for DKD and albuminuria.^{30,38,44
-46,51} The analysis demonstrated an overall AUC of 0.63 for diagnosing DKD and albuminuria (AUC: 0.63, 95% CI: 0.58–0.68; Figure 5). Subgroup analysis showed no significant difference between LAP (AUC: 0.62, 95% CI: 0.52–0.72), VAI (AUC: 0.62, 95% CI: 0.54–0.69) and AIP (AUC: 0.64, 95% CI: 0.52–0.76; P of difference = .93). Nabipoorashrafi et al reported a sensitivity of 48% and a specificity of 61% at a cut-off of 6.9 for VAI.³⁰ They also showed lower sensitivity (39%) and higher specificity (75%) at 93.19 for LAP in detecting albuminuria.³⁰ Moreover, Qi et al³⁸ found a sensitivity of 64.8% and a specificity of 82.8% with a cut-off of 0.415 for AIP in patients with albuminuria. In contrast, lower values (sensitivity: 58.8%, specificity: 55%) with a cut-off of 0.126 were found in another study for AIP in patients with DKD.⁴⁵

Figure 5.

Forest plot for pooling AUCs for diagnosis of DKD and albuminuria.

Diabetic Retinopathy (DR) and Lipid Biomarkers

Meta-Analysis of Lipid Biomarkers in Patients with and Without DR

Seven studies were identified that compared lipid biomarker values in patients with and without DR.^{32,36,41,43
-45,47} Analysis demonstrated no substantial differences in LAP (WMD: 5.18, 95% CI: −12.40 to 22.76, P = .56; Figure 6A), AIP (WMD: 0.02, 95% CI: −0.02 to 0.05, P = .33; Supplemental Figure 6B), and VAI (WMD: −0.01, 95% CI: −0.22 to 0.20, P = .91; Figure 7) between patients with and without DR. Given the significant heterogeneity across studies, sensitivity analyses and meta-regression were performed. Sensitivity analysis suggested that the findings of each study comparing LAP (Supplemental Figure 8) and VAI (Supplemental Figure 9) in patients with and without DR were robust. However, sensitivity analysis for AIP showed a non-robust finding (Supplemental Figure 10). Additionally, Egger’s test indicated no publication bias among studies comparing LAP (P = .246), AIP (P = .492), and VAI (P = .343). Meta-regression identified mean SBP, DBP, and triglyceride in patients with and without DR as potential sources of heterogeneity (Table 2).

Figure 6.

(A) Forest plot for analysis comparing the LAP levels in patients with DR and albuminuria compared to those without these complications and (B) forest plot for analysis comparing the AIP levels in patients with DR and albuminuria compared to those without these complications.

Figure 7.

A forest plot for analysis comparing the VAI levels in patients with DR and albuminuria compared to those without these complications.

Diagnostic Efficacy of Lipid Biomarkers for DR

Three studies evaluated the diagnostic efficacy of lipid biomarkers in detecting DR.^36,44,45 A meta-analysis of AUC values indicated an AUC of 0.60 for diagnosing DR (AUC: 0.60, 95% CI: 0.47–0.72; Figure 8). LAP demonstrated the highest diagnostic power (AUC: 0.73, 95% CI: 0.65–0.80), with a sensitivity of 84.3% and a specificity of 49.2% at a cut-off value of 37.56.³⁶ This was followed by the AIP (AUC: 0.54, 95% CI: 0.52–0.57) and VAI (AUC: 0.53, 95% CI: 0.45–0.60). The analysis showed a significant difference between the discriminatory power of the markers (P < .01).

Figure 8.

Forest plot for pooling AUCs for diagnosis of DR.

Diabetic Neuropathy (DN) and Lipid Biomarkers

Only 2 studies met the inclusion criteria for assessing lipid biomarkers in patients with and without DN.^29,48 Miric et al reported significantly higher AIP values in patients with diabetic peripheral neuropathy (DPN) compared to those without DPN (0.366 ± 0.238 vs 0.270 ± 0.229; P < .05).²⁹ However, Zhang et al found no significant association between AIP and risk of DN (OR: 0.78, 95% CI: 0.59–1.04, P = .18).

Quality Assessment

21 studies were considered as low risk of bias or high-quality, and 2 studies were categorized as moderate risk of bias. Supplemental Table 2 shows the quality assessment of the included studies. The GRADE Summary of Findings and GRADE Evidence Profile tables (Supplemental Tables 3 and 4) present a detailed overview of the certainty of evidence across all outcomes.

Discussion

Recently, researchers have increasingly investigated the relationship between novel lipid biomarkers and complications associated with DM, specifically DR and DKD. This study compiled available data to assess the lipid biomarkers in individuals with and without microvascular complications. The analysis demonstrated significantly higher levels of lipid biomarkers, including VAI, LAP, and AIP, in patients with DKD and albuminuria than in patients without these complications. Conversely, no notable differences were detected between patients with and without DR. Additionally, the study assessed the discriminatory power of these biomarkers, revealing that these markers exhibited a poor ability to differentiate patients with DR and DKD.

The AIP, representing the log TG/HDL-C ratio, serves as an independent marker that can improve cardiovascular risk assessment compared to traditional lipid markers.⁵² The AIP reflects the balance between elevated TG and reduced HDL-C, both of which are common in dyslipidemia. Additionally, it might act as a useful screening method in the early stages of the detection of diseases associated with dyslipidemia.

The LAP was first introduced as a cost-effective indicator of visceral fat, utilizing measurements of WC and HDL-C to assess the risk of metabolic disorders, particularly those related to obesity. An elevated LAP indicates a higher accumulation of WC and lower HDL-C levels, which are linked to IR, oxidative stress, and inflammation in DM.⁵³ Evidence suggests that LAP acts as a better indicator of metabolic syndrome (MetS) compared to traditional lipid markers, such as BMI, WC, and the waist-to-hip ratio (WHR).⁵⁴ These findings support the utility of LAP as a unique and valuable marker for assessing and detecting MetS-related conditions, including the microvascular complications associated with DM.

Among the lipid biomarkers mentioned, the VAI is the most recently developed. It integrates components from both the LAP and the AIP, including WC, HDL-C, and TG. Elevated VAI levels reflect increased WC and TG, along with decreased HDL-C. By incorporating multiple lipid indicators, VAI provides a more accurate tool for assessing cardiometabolic risk and phenotypes.⁵⁵

Diabetic Kidney Disease and Lipid Biomarkers

Investigations have revealed that individuals suffering from DKD exhibit notable alterations of lipid profiles, characterized by increased TG and low-density lipoprotein cholesterol (LDL-C), alongside reduced HDL-C levels.⁵⁶ Elevated TG levels are mediated through the activation of hormone-sensitive lipase, which releases free fatty acids (FFA) from adipose tissue, and is subsequently converted into TG in the liver.⁵⁷ Additionally, DKD is associated with increased levels of apolipoprotein B100 (APO-B100) produced in the liver and incorporated into LDL-C particles.⁵⁸ Consequently, elevated APO-B100 contributes to the formation and increased numbers of LDL-C particles.⁵⁹ The mechanisms underlying reduced HDL-C levels in patients with DKD remain unclear. However, the production of apolipoprotein A1 (APO-A1), a primary component of HDL-C, is insulin-dependent.⁶⁰ IR may therefore decrease HDL-C levels by impairing APO-A1 activation. TG binds to specific receptors on mesangial cells and podocytes, triggering the release of pro-inflammatory cytokines and reactive oxygen species (ROS), which promote the synthesis of extracellular matrix (ECM).⁶¹ This process contributes to glomerulosclerosis and tubulointerstitial fibrosis.⁵⁹ Moreover, the accumulation of ECM enhances foam cell formation via the uptake of oxidized LDL-C, further exacerbating the inflammatory state.⁵⁹ These mechanisms illustrate how lipid profile alterations contribute to the development of DKD.

Increased DKD risk in relation to higher AIP levels is supported by observations of higher TG and lower HDL-C in individuals with DKD, which was explained previously. A linear J-shaped association exists between the risk of DKD and AIP levels,^46,47 with higher baseline AIP levels significantly increasing the probability of DKD.^35,46,47 Included studies also indicated that patients with the highest AIP levels exhibit a meaningful higher DKD risk as opposed to the lowest group.^46,48 In addition to significantly higher levels of AIP in patients with DKD and albuminuria, existing findings also support this meaningful association and probable predictive role of AIP in relation to DKD.

Similarly, an elevated VAI is linked to a higher risk of DKD and albuminuria, driven by elevated TG and WC, combined with reduced HDL-C in individuals with DM. Apart from the markedly higher VAI values detected in individuals with DKD and albuminuria, pooled ORs calculated from logistic regression analyses confirmed that VAI is independently associated with DKD risk even when controlling for potential cofounders. Furthermore, patients in the highest VAI group had an elevated DKD risk against individuals with lower VAI values.^34,51 These findings underscore the importance of VAI in assessing both the diagnosis and prognosis of individuals with DKD.

Despite significantly higher LAP values in individuals with DKD and albuminuria, the analysis demonstrated only a very weak increase in the risk of albuminuria per one-unit rise in LAP. A similar observation was made regarding the prevalence of DKD concerning LAP, even following the correction for cofounders.^41,51 Conversely, a retrospective study reported a notable positive correlation between LAP levels and DKD risk, where the highest quartile of LAP showed the greatest OR for DKD risk.⁴⁰ Comparable findings were also reported by Sun et al.⁵¹ However, several limitations in studies examining the association between LAP levels and DKD must be considered. First, all these studies were cross-sectional, which complicates the establishment of causal relationships. Second, some studies acknowledged not adjusting their findings for certain confounding variables due to insufficient data. These limitations highlight the necessity of prospective studies involving larger cohorts and detailed patient information to accurately evaluate the association between LAP values and DKD.

The correlation between lipid biomarker values and DKD severity has not been extensively studied. Patients with macroalbuminuria exhibited significantly higher levels of AIP, VAI, and LAP compared to those with microalbuminuria, indicating that these biomarkers may serve as indicators of DKD severity.^45,49 Furthermore, patients with an estimated glomerular filtration rate (eGFR) of less than 30 mL/min had elevated VAI and LAP values compared to other patient groups.^37,49 Notably, the prognostic risk of DKD was positively correlated with VAI and LAP values.⁴⁹ Future research should explore the specific cut-off values of these markers to aid in staging the severity of DKD and albuminuria.

The analysis demonstrated that lipid biomarkers had poor discriminatory power for DKD and albuminuria. The analysis also showed no significant difference between the discriminatory power of these biomarkers (P = .91). Additionally, LAP and the VAI showed higher AUCs compared to traditional indicators, such as BMI and WC.⁵¹ Similar results were observed for the AIP when compared to the WHR, TG, and HDL-C.^38,41 However, conflicting evidence exists regarding other novel markers, such as the triglyceride-glucose (TyG) index. While two studies reported slightly higher AUCs for the TyG index compared to AIP, LAP, and VAI,^30,46 a pooled analysis of the included studies revealed similar or even higher AUC values for LAP and VAI than TyG index and homeostasis model assessment of insulin resistance (HOMA-IR).⁶² Consequently, although a significant association was observed between DKD and albuminuria with these lipid biomarkers, their discriminatory power was categorized as poor, indicating that they may not perform as effectively as other metabolic markers

Diabetic Retinopathy and Lipid Biomarkers

There are inconsistent findings regarding the association between AIP levels and DR. According to Xu et al,⁴⁶ individuals exhibiting elevated AIP levels showed a notably higher risk of DR, while other studies found no substantial association.^33,47,63 The analysis of the included studies did not reveal significant differences in AIP values between the DR and non-DR individuals. This may be explained by the complex interactions between plasma lipids and microvascular complications. Lipid alterations in DM are tissue-specific, and the levels of various lipids do not consistently change in the same manner across different tissues, such as the kidney, nervous system, and retina.⁶⁴ Additionally, diabetic mice exhibit a reduction in overall lipid content in renal and retinal tissues.^64,65 This evidence points to the requirement for the continuation of biological studies to clarify the intricate relationships between lipid profile components and the development of microvascular complications.

The included studies demonstrated inconsistent findings regarding the association of obesity-related markers, such as the LAP and VAI, with DR. While some studies reported no significant association,^41,44 others identified both positive and negative associations between the DR risk and the levels of these indices.^32,36,43 The analysis showed no meaningful differences in LAP and VAI values in the DR and non-DR patient groups. These findings may be influenced by disease duration. Adults with a longer duration of DM often exhibit a meaningful reduction in fat mass (FM), which is linked to decreased levels of these markers. Furthermore, longer disease duration statistically contributed to increased risk of DR.^39,66 Consequently, it is plausible to observe an inverse association between the risk of DR and these markers’ values in individuals with long-term DM. Conversely, patients in the early stages of DM are typically under stringent control of hemoglobin A1c (HbA1c) and fasting blood sugar (FBS), which can be associated with a lower risk of DR despite elevated marker levels.⁴⁴ Additionally, these markers have demonstrated a stronger association with DKD and overall renal function, which may reduce their observed correlation with DR.⁶⁷ Therefore, a significant relationship may become apparent when analyses adjust for disease duration.

The LAP demonstrated significantly higher diagnostic power for DR compared to other markers (P < .01). However, the overall diagnostic performance of these markers was classified as poor. Furthermore, these markers did not exhibit a substantial correlation with DR. Therefore, their prognostic and diagnostic value for DR should be interpreted with caution.

Strengths and Limitations

This study has several notable strengths. It is the first systematic review and meta-analysis to comprehensively evaluate the associations between novel lipid biomarkers, including VAI, LAP, and AIP, and microvascular complications in DM, providing an integrated overview of their diagnostic utility. The inclusion of a large and diverse sample across multiple studies enhances the generalizability of the findings. Furthermore, the systematic evaluation of both diagnostic performance and disease association offers valuable insights into the potential of these biomarkers for early detection and risk stratification, particularly in DKD. By addressing gaps in the existing literature and highlighting the predictive capabilities of these biomarkers, this study establishes a foundation for future research aimed at refining diagnostic strategies and improving clinical management in DM.

Despite the valuable findings, it is essential to consider the limitations. Firstly, there is a notable lack of data regarding diabetic nephropathy (DN), as only 2 studies met the criteria for assessing the relationship between lipid biomarkers and this microvascular complication. This gap highlights the need for further research focusing on this area. Second, the analyses exhibited high heterogeneity, driven by variations in study populations, biomarker measurement techniques, and confounding factors such as diabetes duration and metabolic control. This heterogeneity may have affected the precision and reliability of the pooled estimates. Third, the majority of the included studies employed a cross-sectional design, restricting the ability to infer causal relationships between lipid biomarkers and the development or progression of diabetic complications. Fourth, the included indices were measured in different laboratories, and varying cut-offs were reported for assessing microvascular complications. These inconsistencies may have led to discrepancies in the included findings and prevented the determination of specific cut-offs for each biomarker. Finally, there is a geographic bias in the study sample, with most studies originating from China and other parts of Asia. This regional concentration may affect the ability to apply the results to populations in other parts of the world, where genetic, environmental, and lifestyle factors may differ significantly.

Conclusion

This study demonstrates that novel lipid biomarkers are significantly associated with DKD and albuminuria in patients with DM. Despite their strong statistical association with renal complications, these markers exhibited limited diagnostic accuracy, as reflected by poor area-AUC values. This suggests that while they may serve as adjunct indicators of DKD risk, their standalone utility for clinical prediction remains constrained. In contrast, no significant association was observed between these biomarkers and DR, and their diagnostic performance for DR was similarly suboptimal. The lack of correlation underscores the tissue-specific nature of lipid-mediated pathology in diabetes, where systemic lipid alterations may disproportionately affect renal microvasculature compared to retinal tissues.

These findings highlight the potential role of VAI, LAP, and AIP in risk stratification for DKD, though their poor discriminative power necessitates further refinement to improve clinical applicability. Future research should prioritize longitudinal studies to validate causality and investigate whether integrating these markers with other metabolic indices enhances predictive value for microvascular complications.

Supplemental Material

sj-docx-1-end-10.1177_11795514251365301 – Supplemental material for Novel Lipid Biomarkers and Microvascular Complications in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis

Supplemental material, sj-docx-1-end-10.1177_11795514251365301 for Novel Lipid Biomarkers and Microvascular Complications in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis by Diar Zooravar, Shayan Shojaei, Asma Mousavi, Pedram Soltani, Bahareh Shateri Amiri and Hanieh Radkhah in Clinical Medicine Insights: Endocrinology and Diabetes

Supplemental Material

sj-docx-2-end-10.1177_11795514251365301 – Supplemental material for Novel Lipid Biomarkers and Microvascular Complications in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis

Supplemental material, sj-docx-2-end-10.1177_11795514251365301 for Novel Lipid Biomarkers and Microvascular Complications in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis by Diar Zooravar, Shayan Shojaei, Asma Mousavi, Pedram Soltani, Bahareh Shateri Amiri and Hanieh Radkhah in Clinical Medicine Insights: Endocrinology and Diabetes

Supplemental Material

sj-docx-3-end-10.1177_11795514251365301 – Supplemental material for Novel Lipid Biomarkers and Microvascular Complications in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis

Supplemental material, sj-docx-3-end-10.1177_11795514251365301 for Novel Lipid Biomarkers and Microvascular Complications in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis by Diar Zooravar, Shayan Shojaei, Asma Mousavi, Pedram Soltani, Bahareh Shateri Amiri and Hanieh Radkhah in Clinical Medicine Insights: Endocrinology and Diabetes

Supplemental Material

sj-docx-4-end-10.1177_11795514251365301 – Supplemental material for Novel Lipid Biomarkers and Microvascular Complications in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis

Supplemental material, sj-docx-4-end-10.1177_11795514251365301 for Novel Lipid Biomarkers and Microvascular Complications in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis by Diar Zooravar, Shayan Shojaei, Asma Mousavi, Pedram Soltani, Bahareh Shateri Amiri and Hanieh Radkhah in Clinical Medicine Insights: Endocrinology and Diabetes

Footnotes

Acknowledgements

None.

ORCID iDs

Shayan Shojaei

Asma Mousavi

Ethical Considerations

Not applicable. This study is a systematic review and meta-analysis of previously published data and did not involve direct interaction with human subjects. Therefore, ethical approval and participant consent were not required.

Consent for Publication

Not applicable. No individual data or identifiable images are included in this article.

Author Contributions

Diar Zooravar: Conceptualization; Formal analysis; Investigation; Visualization; Writing - original draft. Shayan Shojaei: Conceptualization; Investigation; Methodology; Supervision; Writing - original draft. Asma Mousavi: Methodology; Project administration; Writing - original draft. Pedram Soltani: Writing - original draft. Bahareh Shateri Amiri: Writing - review & editing. Hanieh Radkhah: Methodology; Project administration; Supervision; Validation; Writing - review & editing.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

All data generated or analyzed during this study are included in this published article and its supplementary information files. Additional information is available from the corresponding author upon reasonable request.

Supplemental Material

Supplemental material for this article is available online.

References

Dilworth

Facey

Omoruyi

Diabetes mellitus and its metabolic complications: the role of adipose tissues. Int J Mol Sci. 2021;22:7644.

Ali

Pearson-Stuttard

Selvin

Gregg

EW.

Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia. 2022;65:3-13.

Hazar

Jokar

Namavari

Hosseini

Rahmanian

An updated systematic review and meta-analysis of the prevalence of type 2 diabetes in Iran, 1996-2023. Front Public Health. 2024;12:1322072.

Chawla

Jaggi

Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum?

Indian J Endocrinol Metab. 2016;20:546-551.

Kulkarni

Thool

Daigavane

Understanding the clinical relationship between diabetic retinopathy, nephropathy, and neuropathy: a comprehensive review. Cureus. 2024;16:e56674.

Vithian

Hurel

Microvascular complications: pathophysiology and management. Clin Med. 2010;10:505-509.

Jyotsna

Ahmed

Kumar

, et al. Exploring the complex connection between diabetes and cardiovascular disease: analyzing approaches to mitigate cardiovascular risk in patients with diabetes. Cureus. 2023;15:e43882.

Ibrahim

MM.

Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11-18.

Freedland

ES.

Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab. 2004;1:12.

10.

Misra

Vikram

NK.

Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition. 2003;19:457-466.

11.

Martínez-Sánchez

Vargas-Abonce

Rocha-Haro

, et al. Visceral adiposity index is associated with insulin resistance, impaired insulin secretion, and β-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Epidemiol Manage. 2021;2:100013.

12.

Hulkoti

Acharya

Shukla

, et al. Visceral adiposity index in type 2 diabetes mellitus (DM) and its correlation with microvascular complications. Cureus. 2022;14:e31279.

13.

Chen

Liu

Zhuang

, et al. Lipid accumulation product is a better predictor of metabolic syndrome in Chinese adolescents: a cross-sectional study. Front Endocrinol. 2023;14:1179990.

14.

Bikov

Frent

Reisz

, et al. Comparison of composite lipid indices in patients with obstructive sleep apnoea. Nat Sci Sleep. 2022;14:1333-1340.

15.

Fakhrolmobasheri

Abhari

Heidarpour

, et al. Lipid accumulation product and visceral adiposity index for incidence of cardiovascular diseases and mortality; results from 13 years follow-up in Isfahan cohort study. Obes Sci Pract. 2024;10:e713.

16.

Tao

, et al. Association between physical activity and visceral adiposity index (VAI) in U.S. population with overweight or obesity: a cross-sectional study. BMC Public Health. 2024;24:2314.

17.

Huo

Association between visceral adiposity index, lipid accumulation product and type 2 diabetes mellitus in US adults with hypertension: a cross-sectional analysis of NHANES from 2005 to 2018. BMC Endocr Disord. 2024;24:216.

18.

Tamini

Bondesan

Caroli

Sartorio

The lipid Accumulation Product Index (LAP) and the Cardiometabolic Index (CMI) are useful for predicting the presence and severity of metabolic syndrome in adult patients with obesity. J Clin Med. 2024;13:2843.

19.

Kao

Chang

Chen

LW.

Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: a 9-year longitudinal study. Sci Rep. 2021;11:9900.

20.

Page

McKenzie

Bossuyt

, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol. 2021;74:790-799.

21.

Stang

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605.

22.

Mertz

Loeb

Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45.

23.

Luo

Wan

Liu

Tong

Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785-1805.

24.

Wan

Wang

Liu

Tong

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

25.

DerSimonian

Laird

Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.

26.

Çorbacıoğlu

ŞK

Aksel

. Receiver operating characteristic curve analysis in diagnostic accuracy studies: a guide to interpreting the area under the curve value. Turk J Emerg Med. 2023;23:195-198.

27.

Sterne

JAC

Egger

Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046-1055.

28.

Durak Keskinler

Feyizoglu

, et al. An observational study on the association between surrogates of visceral adiposity and albuminuria in type 2 diabetes. Clin Diabetol. 2024;13:216-223.

29.

Miric

Kisic

Filipovic-Danic

, et al. Xanthine oxidase activity in type 2 diabetes mellitus patients with and without diabetic peripheral neuropathy. J Diabetes Res. 2016;2016:4370490.

30.

Nabipoorashrafi

Adeli

Seyedi

, et al. Comparison of insulin resistance indices in predicting albuminuria among patients with type 2 diabetes. Eur J Med Res. 2023;28:166.

31.

Rammaiah

Deverbhavi

Thirumala

KR.

Plasma lipid profile and cardiac risk markers in diabetic nephropathy. J Evol Med Dent Sci. 2020;9:516-519.

32.

Chen

Niu

, et al. Association of visceral obesity indices with incident diabetic retinopathy in patients with diabetes: prospective cohort study. JMIR Public Health Surveill. 2024;10:e48120.

33.

Chen

Zhang

Gong

, et al. The link between diabetic retinal and renal microvasculopathy is associated with dyslipidemia and upregulated circulating level of cytokines. Front Public Health. 2022;10:1040319.

34.

Wang

Zhang

, et al. Association between visceral adiposity index and incidence of diabetic kidney disease in adults with diabetes in the United States. Sci Rep. 2024;14:17957.

35.

Miao

Zhong

Zhu

Atherogenic Index of plasma as an early marker of chronic kidney disease and liver injury in type 2 diabetes. Clin Med Insights Endocrinol Diabetes. 2024;17:11795514241259741.

36.

Zhang

Tong

Gao

XY.

Association among lipid accumulation product, Chinese visceral obesity index and diabetic retinopathy in patients with type 2 diabetes: a cross-sectional study. Diabetes Metab Syndr Obes. 2021;14:4971-4979.

37.

Lee

Lin

Wen

Hsu

Chen

SC.

Obesity-related indices are associated with albuminuria and advanced kidney disease in type 2 diabetes mellitus. Ren Fail. 2021;43:1250-1258.

38.

Kang

Chen

Deng

Chen

Predictive value of plasma atherogenic index for microalbuminuria in newly diagnosed patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2022;15:1245-1252.

39.

Sun

Liu

Zhang

Zeng

Kang

The correlation of prediabetes and type 2 diabetes with adiposity in adults. Front Nutr. 2022;9:818263.

40.

Tang

Yao

Cao

, et al. Interrelation between the lipid accumulation product index and diabetic kidney disease in patients with type 2 diabetes mellitus. Front Endocrinol. 2023;14:1224889.

41.

Wan

Wang

Xiang

, et al. Associations between abdominal obesity indices and diabetic complications: Chinese visceral adiposity index and neck circumference. Cardiovasc Diabetol. 2020;19:118.

42.

Wen

Yuan

Independent association between the visceral adiposity index and microalbuminuria in patients with newly diagnosed type 2 diabetes. Diabetes Metab Res Rev. 2020;36:e3198.

43.

Zhong

Yue

, et al. Association between lipid accumulation product and diabetic retinopathy based on a community-based survey in Chinese with type 2 diabetes. Diabetes Metab Syndr Obes. 2019;12:513-518.

44.

Kang

, et al. Association of visceral adiposity index with incident nephropathy and retinopathy: a cohort study in the diabetic population. Cardiovasc Diabetol. 2022;21:32.

45.

Zhou

Xiang

Association of Atherogenic Index of plasma with retinopathy and nephropathy in adult patients with type 2 diabetes mellitus aged >18 years. Can J Diabetes. 2022;46:708-714.

46.

Yan

Zhou

Wang

, et al. Associations between cardiometabolic indices and the risk of diabetic kidney disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2024;23:142.

47.

Zhang

Liu

Peng

, et al. Impact of baseline and trajectory of the atherogenic index of plasma on incident diabetic kidney disease and retinopathy in participants with type 2 diabetes: a longitudinal cohort study. Lipids Health Dis. 2024;23:11.

48.

Zhang

Yang

Wan

Association between atherogenic index of plasma and type 2 diabetic complications: a cross-sectional study. Front Endocrinol. 2025;16:1537303.

49.

Zhao

Zhou

Association of different obesity indexes with diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study. Sci Rep. 2024;14:21571.

50.

Zhou

Zhang

Yang

, et al. Associations between visceral adiposity index and incident nephropathy outcomes in diabetic patients: Insights from the ACCORD trial. Diabetes Metab Res Rev. 2023;39:e3602.

51.

Sun

Wang

Yun

, et al. Correlation between the variability of different obesity indices and diabetic kidney disease: a retrospective cohort study based on populations in Taiwan. Diabetes Metab Syndr Obes. 2023;16:2791-2802.

52.

Rabiee Rad

Ghasempour Dabaghi

Darouei

Amani-Beni

. The association of atherogenic index of plasma with cardiovascular outcomes in patients with coronary artery disease: a systematic review and meta-analysis. Cardiovasc Diabetol. 2024;23:119.

53.

Mirmiran

Bahadoran

Azizi

Lipid accumulation product is associated with insulin resistance, lipid peroxidation, and systemic inflammation in type 2 diabetic patients. Endocrinol Metabol. 2014;29:443-449.

54.

Witarto

Visuddho

, et al. Gender-specific accuracy of lipid accumulation product index for the screening of metabolic syndrome in general adults: a meta-analysis and comparative analysis with other adiposity indicators. Lipids Health Dis. 2024;23:198.

55.

Dong

Bai

Cai

Zhou

Ding

Visceral adiposity index performed better than traditional adiposity indicators in predicting unhealthy metabolic phenotype among Chinese children and adolescents. Sci Rep. 2021;11:23850.

56.

Palazhy

Viswanathan

Lipid abnormalities in type 2 diabetes mellitus patients with overt nephropathy. Diabetes Metab J. 2017;41:128-134.

57.

Mooradian

AD.

Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150-159.

58.

Bonnet

Cooper

ME.

Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab. 2000;26:254-264.

59.

Kawanami

Matoba

Utsunomiya

Dyslipidemia in diabetic nephropathy. Ren Replace Therapy. 2016;2:16.

60.

Adler

Stevens

Manley

Bilous

Cull

Holman

RR.

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225-232.

61.

Nishida

Oda

Yorioka

Effect of lipoproteins on mesangial cell proliferation. Kidney Int Suppl. 1999;71:S51-S53.

62.

Liu

Xia

Song

, et al. Association between the triglyceride-glucose index and diabetic nephropathy in patients with type 2 diabetes: a cross-sectional study. J Diabetes Invest. 2021;12:557-565.

63.

Zhang

Qiu

Wang

, et al. Dysregulated serum lipid metabolism promotes the occurrence and development of diabetic retinopathy associated with upregulated circulating levels of VEGF-A, VEGF-D, and PlGF. Front Med. 2021;8:779413.

64.

Sas

Lin

Rajendiran

, et al. Shared and distinct lipid-lipid interactions in plasma and affected tissues in a diabetic mouse model. J Lipid Res. 2018;59:173-183.

65.

Eid

Sas

Abcouwer

, et al. New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism. Diabetologia. 2019;62:1539-1549.

66.

Cardoso

CRL

Leite

Dib

Salles

. Predictors of development and progression of retinopathy in patients with type 2 diabetes: Importance of blood pressure parameters. Sci Rep. 2017;7:4867.

67.

Moh

Neelam

Zhang

, et al. Excess visceral adiposity is associated with diabetic retinopathy in a multiethnic Asian cohort with longstanding type 2 diabetes. Endocr Res. 2018;43:186-194.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.58 MB

0.03 MB